Literature DB >> 35446649

ESCRT-mediated membrane repair protects tumor-derived cells against T cell attack.

Alex T Ritter1, Gleb Shtengel2, C Shan Xu2, Aubrey Weigel2, David P Hoffman2, Melanie Freeman2, Nirmala Iyer2, Nensi Alivodej2, David Ackerman2, Ilia Voskoboinik3, Joseph Trapani3, Harald F Hess2, Ira Mellman1.   

Abstract

Cytotoxic T lymphocytes (CTLs) and natural killer cells kill virus-infected and tumor cells through the polarized release of perforin and granzymes. Perforin is a pore-forming toxin that creates a lesion in the plasma membrane of the target cell through which granzymes enter the cytosol and initiate apoptosis. Endosomal sorting complexes required for transport (ESCRT) proteins are involved in the repair of small membrane wounds. We found that ESCRT proteins were precisely recruited in target cells to sites of CTL engagement immediately after perforin release. Inhibition of ESCRT machinery in cancer-derived cells enhanced their susceptibility to CTL-mediated killing. Thus, repair of perforin pores by ESCRT machinery limits granzyme entry into the cytosol, potentially enabling target cells to resist cytolytic attack.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35446649     DOI: 10.1126/science.abl3855

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   63.714


  4 in total

Review 1.  The ESCRT Machinery: Remodeling, Repairing, and Sealing Membranes.

Authors:  Yolanda Olmos
Journal:  Membranes (Basel)       Date:  2022-06-19

2.  Caspase-7 and acid sphingomyelinase: partner repairmans of gasdermin and perforin pores.

Authors:  Ke Jin; Guofang Shen
Journal:  Signal Transduct Target Ther       Date:  2022-08-22

3.  ESCRT machinery: role of membrane repair mechanisms in escaping cell death.

Authors:  Lisa Gregor; Sophia Stock; Sebastian Kobold
Journal:  Signal Transduct Target Ther       Date:  2022-07-16

Review 4.  New insights into CAR T cell-mediated killing of tumor cells.

Authors:  David Espie; Emmanuel Donnadieu
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.